Claims for Patent: 10,940,146
✉ Email this page to a colleague
Summary for Patent: 10,940,146
| Title: | NHE3-binding compounds and methods for inhibiting phosphate transport |
| Abstract: | Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent. |
| Inventor(s): | Christopher Carreras, Dominique Charmot, Jeffrey W. Jacobs, Eric Labonte, Jason G. Lewis |
| Assignee: | Ardelyx Inc |
| Application Number: | US16/351,225 |
| Patent Claims: |
1. A method for inhibiting phosphate uptake in the gastrointestinal tract of a patient in need of phosphate lowering, comprising enterally administering to the patient an effective amount of a compound having the structure of Formula (X): wherein NHE is L is a polyalkylene glycol linker; n is 2; and Core is selected from: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the polyalkylene glycol linker is polyethylene glycol. 3. A method for treating hyperphosphatemia in a subject in need thereof, comprising enterally administering to the patient an effective amount of a compound having the structure of Formula (X): wherein NHE is L is a polyalkylene glycol linker; n is 2; and Core is selected from: or a pharmaceutically acceptable salt thereof. 4. The method of claim 3, wherein the polyalkylene glycol linker is polyethylene glycol. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch